|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Nycomed International Management GmbH, a Germany-based pharmaceutical company focused on dermatology. |
|---|---|
| Transferring Party | Bradley Pharmaceuticals, Inc. BDY, a manufacturer of branded prescription and OTC drugs and other products relating to dermatological and respiratory therapy. |
| Sector | Biopharmaceuticals |
| Date | October 30, 2007 |
| Analysis Both Nycomed and Bradley have a dermatology focus and are active in branded and generic areas. Provides Nycomed US with additional branded dermatologics to build on its PharmaDerm division and the opportunity to enhance its platform for acquisition, in-licensing and co-promotion. Deal value -- $346m, on sales of $141.2m (2.5x) and EBITDA of $25.7m (13.5x). Deal resulted from an auction. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |